Administration of Yunnan Baiyao or Xingnaojing in patients with moderate-to-severe traumatic brain injury and craniotomy
AssigneeLotus Biotech.com LLC
InventorsGuoqiang Xing, Xiaodong Ma
Life of this patent
Estimating the term…
Abstract
Clinically validated methods of administering Yunnan Baiyao or Xingnaojing can improve postoperative recovery and long-term clinical prognosis of patients with moderate-to-severe traumatic brain injury (TBI) and emergency craniotomy. Both medicinal methods are useful for minimizing or inhibiting the adverse impacts of secondary injury, oxidative damage and neuroinflammation associated with TBI, spinal cord injury, craniotomy/craniectomy, cerebral hemostasis and hemorrhage, coagulopathy, stroke, neural injury and neuroinflammation, and for promoting the long-term functional recovery and well-being of the patients with the afore-mentioned diseases.
Claims7
A method of treating a patient recovering from emergency craniotomy due to moderate-to-severe traumatic brain injury (TBI) comprising administering to the patient both orthodox therapy (OT) and a therapeutically effective amount of Yunnan Baiyao (YB) for seven consecutive days in an intensive care setting, wherein in comparison to patients receiving OT alone:
- acute postoperative neurological recovery of the patient is improved as measured by Glasgow Coma Scale (GCS) during postoperative days 1, 3, 5, and 7;
- long-term functional outcome of the patient is improved as measured by Glasgow Outcome Scale (GOS) and Karnofsky Performance Status (KPS) at 30 and 90 days;
- and
- secondary-injury biomarkers are modulated by reducing serum S100B levels and preserving or restoring serum superoxide dismutase (SOD) activity.
Dependencies are inferred from the claim text.